28320554|t|Pregnancy and Kidney Outcomes in Patients With IgA Nephropathy: A Cohort Study
28320554|a|The outcomes of pregnancy in immunoglobulin A nephropathy (IgAN) are controversial. This cohort study assessed the effects of pregnancy on kidney disease progression and risk factors for adverse pregnancy outcomes in patients with IgAN. A cohort study. Women of child-bearing age with IgAN and minimum follow-up of 1 year after biopsy from December 2003 to September 2014. Pregnancy, treated as a time-dependent variable; baseline (at time of biopsy) estimated glomerular filtration rate (eGFR), proteinuria, blood pressure, and kidney pathology (Oxford MEST classification). Kidney disease progression event, defined as 30% decline in eGFR or end-stage kidney disease; rate of eGFR decline; and adverse pregnancy outcomes, including severe preeclampsia and fetal loss. Of 413 patients enrolled, 266 (64.4%), 101 (24.5%), 40 (9.6%), and 6 (1.5%) had chronic kidney disease (CKD) stages 1, 2, 3, and 4, respectively. During follow-up, 104 had 116 pregnancies, of which 110 continued beyond week 20; 309 patients did not become pregnant. After adjustment for age, eGFR, mean arterial pressure, proteinuria, and pathology class at the time of biopsy, subsequent pregnancy among patients with CKD stages 3 to 4, but not CKD stages 1 to 2, was associated with faster eGFR decline (-7.44 vs -3.90mL/min/1.73m(2) per year; P=0.007) and increased incidence of kidney progression events (HR, 5.14; 95% CI, 1.16-22.74) compared with patients who did not become pregnant. Relatively small sample size and single-center experience. Pregnancy accelerated kidney disease progression in women with IgAN and CKD stage 3, but not in those at stage 1 or 2.
28320554	0	9	Pregnancy	T033	C0032972
28320554	14	20	Kidney	T023	C0022646
28320554	21	29	Outcomes	T169	C1274040
28320554	33	41	Patients	T101	C0030705
28320554	47	62	IgA Nephropathy	T047	C0017661
28320554	66	78	Cohort Study	T081	C0009247
28320554	83	104	outcomes of pregnancy	T033	C0032972
28320554	108	136	immunoglobulin A nephropathy	T047	C0017661
28320554	138	142	IgAN	T047	C0017661
28320554	168	180	cohort study	T081	C0009247
28320554	205	214	pregnancy	T040	C0032961
28320554	218	224	kidney	T023	C0022646
28320554	225	244	disease progression	T046	C0242656
28320554	249	261	risk factors	T033	C0035648
28320554	266	273	adverse	T033	C1705586
28320554	274	292	pregnancy outcomes	T033	C0032972
28320554	296	304	patients	T101	C0030705
28320554	310	314	IgAN	T047	C0017661
28320554	318	330	cohort study	T081	C0009247
28320554	332	337	Women	T098	C0043210
28320554	341	358	child-bearing age	T033	C1960468
28320554	364	368	IgAN	T047	C0017661
28320554	381	390	follow-up	T058	C1522577
28320554	407	413	biopsy	T060	C0005558
28320554	452	461	Pregnancy	T040	C0032961
28320554	463	470	treated	T169	C1522326
28320554	501	509	baseline	T081	C1442488
28320554	522	528	biopsy	T060	C0005558
28320554	540	566	glomerular filtration rate	T060	C0017654
28320554	568	572	eGFR	T060	C0017654
28320554	575	586	proteinuria	T033	C0033687
28320554	588	602	blood pressure	T040	C0005823
28320554	608	614	kidney	T023	C0022646
28320554	615	624	pathology	T046	C0677042
28320554	626	652	Oxford MEST classification	T185	C0008902
28320554	655	661	Kidney	T023	C0022646
28320554	662	681	disease progression	T046	C0242656
28320554	682	687	event	T051	C0441471
28320554	704	711	decline	T080	C0392756
28320554	715	719	eGFR	T060	C0017654
28320554	723	747	end-stage kidney disease	T047	C0022661
28320554	757	761	eGFR	T060	C0017654
28320554	762	769	decline	T080	C0392756
28320554	775	782	adverse	T033	C1705586
28320554	783	801	pregnancy outcomes	T033	C0032972
28320554	820	832	preeclampsia	T046	C0032914
28320554	837	847	fetal loss	T046	C0687675
28320554	856	864	patients	T101	C0030705
28320554	929	966	chronic kidney disease (CKD) stages 1	T047	C2316401
28320554	968	969	2	T047	C2316786
28320554	971	972	3	T047	C2316787
28320554	978	979	4	T047	C2317473
28320554	1002	1011	follow-up	T058	C1522577
28320554	1025	1036	pregnancies	T040	C0032961
28320554	1081	1089	patients	T101	C0030705
28320554	1094	1113	not become pregnant	T033	C0232973
28320554	1136	1139	age	T032	C0001779
28320554	1141	1145	eGFR	T060	C0017654
28320554	1147	1169	mean arterial pressure	T033	C0428886
28320554	1171	1182	proteinuria	T033	C0033687
28320554	1188	1197	pathology	T091	C0030664
28320554	1219	1225	biopsy	T060	C0005558
28320554	1238	1247	pregnancy	T040	C0032961
28320554	1254	1262	patients	T101	C0030705
28320554	1268	1280	CKD stages 3	T047	C2316787
28320554	1284	1285	4	T047	C2317473
28320554	1295	1307	CKD stages 1	T047	C2316401
28320554	1311	1312	2	T047	C2316786
28320554	1318	1333	associated with	T080	C0332281
28320554	1341	1345	eGFR	T060	C0017654
28320554	1346	1353	decline	T080	C0392756
28320554	1408	1417	increased	T081	C0205217
28320554	1418	1427	incidence	T081	C0021149
28320554	1431	1437	kidney	T023	C0022646
28320554	1438	1449	progression	T169	C0449258
28320554	1450	1456	events	T051	C0441471
28320554	1502	1510	patients	T101	C0030705
28320554	1519	1538	not become pregnant	T033	C0232973
28320554	1551	1556	small	T081	C0700321
28320554	1557	1568	sample size	T081	C0242618
28320554	1599	1608	Pregnancy	T040	C0032961
28320554	1609	1620	accelerated	T169	C0521110
28320554	1621	1627	kidney	T023	C0022646
28320554	1628	1647	disease progression	T046	C0242656
28320554	1651	1656	women	T098	C0043210
28320554	1662	1666	IgAN	T047	C0017661
28320554	1671	1682	CKD stage 3	T047	C2316787
28320554	1704	1711	stage 1	T047	C2316401
28320554	1715	1716	2	T047	C2316786